$32 – $77Price range: $32 through $77
Pronefra is a palatable 5-in-1 oral suspension by Virbac supporting kidney function in cats and dogs with chronic kidney disease (CKD) or elevated phosphorus. Combines two intestinal phosphate binders (calcium + magnesium carbonate), chitosan (uremic toxin binder), marine oligopeptides (blood pressure support), and Astragalus polysaccharides (renal structure). Cats: 1ml per 4kg twice daily. Dogs: 1ml per 5kg twice daily. Available in 60ml and 180ml.
| Size | 60ml, 180ml |
|---|---|
| ANIMALS | Cats, Dogs |
| FORM | Suspension |
36 people are viewing this product right now
🔥 7 items sold in last 3 hours
Best prices
Always FREE delivery
Huge product selection. You can contact us if you need certain product
Pronefra is a palatable oral suspension manufactured by Virbac, formulated to support kidney function in cats and dogs with chronic kidney disease (CKD) or elevated blood phosphorus levels (hyperphosphataemia). It combines five complementary active ingredients in a single chicken liver-flavoured liquid that can be added to food or given directly by the included dosing syringe — making it significantly more practical and palatable than older renal supplements in capsule, powder, or paste form.
Pronefra is a nutritional supplement, not a veterinary medicine. It supports and complements the management of CKD alongside veterinary dietary management, medications, and monitoring — it does not replace them. Always consult your veterinarian before starting Pronefra, particularly in older animals or those on multiple medications.
Chronic kidney disease is one of the leading causes of death in cats over 10 years of age, affecting up to 30% of senior cats and approximately 7% of dogs. As kidney function declines, the kidneys become progressively less able to filter and excrete phosphorus from the blood. Phosphorus accumulates — a condition called hyperphosphataemia — which accelerates further kidney damage through mineralisation of renal tissue, stimulates parathyroid hormone secretion (renal secondary hyperparathyroidism), and contributes to the progression of the disease.
Controlling dietary phosphorus absorption is one of the most evidence-supported interventions in CKD management. Intestinal phosphate binders work in the gut, binding to phosphorus in food before it can be absorbed into the bloodstream, reducing the phosphorus burden on the kidneys.
In addition to phosphorus, declining kidney function leads to the accumulation of uraemic toxins — metabolic waste products (including urea, creatinine, and indoxyl sulphate) that the kidneys cannot adequately clear. These toxins cause the nausea, vomiting, weight loss, and lethargy characteristic of advanced CKD. Binding these toxins in the gut reduces their systemic absorption.
Calcium carbonate binds to dietary phosphorus in the gastrointestinal tract to form insoluble calcium phosphate salts that cannot be absorbed. This reduces the amount of phosphorus entering the bloodstream from food — particularly important at mealtimes, which is why Pronefra must be given with or around food. Calcium carbonate is an established first-line phosphate binder used in veterinary CKD management.
Magnesium carbonate provides a second, complementary mechanism of intestinal phosphate binding. Using two different carbonate binders together provides broader and more effective phosphorus reduction than either alone — an approach supported by clinical experience in veterinary nephrology.
Chitosan is a natural polysaccharide derived from crustacean shells. In the intestinal tract, chitosan binds to uraemic toxins — particularly urea and its breakdown products — reducing their absorption from the gut and lowering the circulating levels of these toxic metabolites. This reduces the toxic burden on the body and helps address the systemic toxaemia that causes many of the clinical signs of CKD (nausea, lethargy, reduced appetite).
Marine oligopeptides, also known as fish protein hydrolysate, are short peptide chains derived from fish protein. These bioactive peptides have been shown in multiple human and animal studies to help support normal blood pressure by inhibiting angiotensin-converting enzyme (ACE) — the same pathway targeted by ACE inhibitor medications like benazepril (Fortekor). Hypertension is extremely common in cats and dogs with CKD (affecting up to 65% of cats with CKD) and directly accelerates kidney damage. Supporting normal blood pressure is therefore a key component of renal protection.
Polysaccharides extracted from Astragalus membranaceus (a traditional medicinal herb) contribute to maintaining the normal structure of the kidney. Astragalus extracts have been studied for their nephroprotective properties — antioxidant activity, anti-inflammatory effects, and reduction of glomerular damage — in experimental models of renal disease.
A published clinical study evaluated Pronefra over 12 weeks in 10 cats (ages 2–5 years) given the supplement alongside their normal food. The results showed:
These results support the use of Pronefra as a practical adjunct to dietary and medical management of CKD in cats.
Give Pronefra twice daily, with food or at mealtimes. Ensure fresh water is available at all times during treatment.
| Species | Dose | Frequency | Example (5kg cat) |
|---|---|---|---|
| Cats | 1ml per 4kg body weight | Twice daily | 5kg cat = 1.25ml twice daily |
| Dogs | 1ml per 5kg body weight | Twice daily | 10kg dog = 2ml twice daily |
Do not exceed the recommended dose. In the case of regurgitation, temporarily reduce the amount slightly for a few days and consult your veterinarian if this persists.
| Weight | Per Dose (ml) | Daily Total (ml) |
|---|---|---|
| Cat 3kg | 0.75ml | 1.5ml/day |
| Cat 4kg | 1.0ml | 2.0ml/day |
| Cat 5kg | 1.25ml | 2.5ml/day |
| Cat 6kg | 1.5ml | 3.0ml/day |
| Dog 5kg | 1.0ml | 2.0ml/day |
| Dog 10kg | 2.0ml | 4.0ml/day |
| Dog 15kg | 3.0ml | 6.0ml/day |
| Dog 20kg | 4.0ml | 8.0ml/day |
| Dog 30kg | 6.0ml | 12.0ml/day |
| Animal | 60ml Bottle | 180ml Bottle |
|---|---|---|
| Cat 4kg (2ml/day) | ~30 days | ~90 days |
| Cat 5kg (2.5ml/day) | ~24 days | ~72 days |
| Dog 10kg (4ml/day) | ~15 days | ~45 days |
| Dog 15kg (6ml/day) | ~10 days | ~30 days |
| Dog 20kg (8ml/day) | ~7.5 days | ~22 days |
For cats and small dogs, the 60ml bottle is suitable for a one-month supply. For dogs over 10–15kg on long-term supplementation, the 180ml bottle is significantly more economical.
Pronefra is suitable for adult cats and dogs that:
Pronefra may not be suitable for some older animals or animals under specific medical treatment for digestive conditions. Always consult your veterinarian before starting — particularly in animals already receiving phosphate binders as part of prescription medication, or those with severe gastrointestinal conditions.
The International Renal Interest Society (IRIS) classifies CKD in cats and dogs into four stages (Stage 1–4) based on creatinine/SDMA levels, with sub-staging for proteinuria and blood pressure. Phosphorus management is recommended from Stage 2 onwards if dietary restriction alone is not achieving phosphorus targets. Pronefra is particularly well-suited to early intervention — Stage 1–2 — where palatability and owner compliance are critical for long-term success.
| Feature | Pronefra (Virbac) | Epakitin | Azodyl |
|---|---|---|---|
| Phosphate binders | Calcium carbonate + Magnesium carbonate (dual) | Calcium carbonate + Chitosan | None |
| Uremic toxin binder | Chitosan | Chitosan | Probiotic bacteria (indirect) |
| Blood pressure support | Marine oligopeptides (ACE-inhibiting peptides) | None | None |
| Renal structure support | Astragalus polysaccharides | None | None |
| Format | Palatable liquid suspension | Powder (added to food) | Capsule (refrigerated) |
| Palatability | High — chicken liver flavoured | Moderate | Low — capsule, refrigerated |
| Given with food? | Yes — at mealtimes | Yes — mixed with food | Separate from food (before meals) |
As soon as your veterinarian identifies elevated phosphorus or early-stage kidney disease (IRIS Stage 1–2). Earlier intervention is more effective than starting at advanced stages — Pronefra helps slow the progression of CKD by reducing the phosphorus-driven damage to remaining kidney tissue. Your vet will typically use blood phosphorus levels and IRIS stage to guide when to start phosphate binders.
Yes — and this is the most common approach. Renal diets reduce dietary phosphorus intake, while Pronefra reduces the absorption of what phosphorus remains in the diet. The two strategies are complementary. Many cats in IRIS Stage 2–3 require both a renal diet AND an intestinal phosphate binder to achieve the IRIS target blood phosphorus levels.
Your veterinarian will monitor blood phosphorus and creatinine levels at regular recheck appointments (typically every 3–6 months in stable CKD). A reduction in blood phosphorus and stable or decreasing creatinine levels suggest the supplement is having its intended effect. Improvement in clinical signs — better appetite, less lethargy, reduced vomiting — may also be seen as uraemic toxin levels are reduced.
Yes — Pronefra’s marine oligopeptides provide blood pressure support through a similar pathway to ACE inhibitors but are not a replacement for prescription ACE inhibitors in cats with proteinuria or hypertension. Pronefra can be used alongside benazepril under veterinary supervision. The two approaches are complementary rather than duplicative.
For cats (typically 4–6kg), the 60ml bottle provides approximately 3–4 weeks’ supply and is suitable for initial trials. For long-term supplementation, the 180ml provides approximately 3 months for most cats. For dogs over 10kg on long-term supplementation, the 180ml is the much more economical choice. See the bottle duration table above for your pet’s specific weight.
Related products: Fortekor Plus (Benazepril + Pimobendan) – ACE Inhibitor for Cardiac & Renal Patients | Cerenia Injectable – Anti-nausea for CKD-related vomiting
You must be logged in to post a review.
Reviews
There are no reviews yet.